Marina Udier, PhD, is the CEO of Nouscom, a clinical stage company with lead asset in Ph2. During her 4-year tenure as the CEO, she led the company through first IND approval and subsequent multiple successful regulatory submissions, a licensing deal (with JnJ), and most recently a successful oversubscribed series C financing ($82M). Prior to Nouscom, Marina was an operating Principal with Versant Ventures. Prior to Versant, Marina spent 7 years with Novartis Pharma in senior development and commercial roles covering oncology and neuroscience.

Marina’s professional career stared at McKinsey & Company healthcare practice in Chicago, working with Fortune 500 companies with focus in marketing, strategy and pricing.

Marina received her PhD in Chemistry from Yale University. She authored peer reviewed publications covering HIV/AIDS research.